Adamas Pharmaceuticals Inc (ADMS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2000||Chairman of the Board, Chief Executive Officer, Co-Founder|
|63||2017||Chief Financial Officer|
|52||2017||Chief Operating Officer|
|53||2016||Senior Vice President - Human Resources|
|42||2017||Principal Accounting Officer|
- BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri
- BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment
- BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia
- BRIEF-Adamas Pharmaceuticals Says As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
- BRIEF-Adamas Q4 Loss Per Share $1.27